0
Errata |

Errata FREE TO VIEW

Chest. 2008;134(4):892. doi:
Text Size: A A A
Published online

In the June 2008 supplement, in the article by Hirsh et al, “Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (Chest 2008; 133[suppl]:71S–109S), on page 99S, in column one, Recommendation 2.5.2, the text should read “For patients with acute ST-segment elevation myocardial infarction receiving fibronolytic therapy who have preserved renal function (< 2.5 mg/dL [220 µmol/L] in males and < 2.0 mg/dL [175 µmol/L] in females), we recommend the use of enoxaparin over UFH, continued up to 8 days (Grade 2A).” The online version has been corrected, and that version should be used.

In the June 2008 supplement, in the article by Goodman et al, “Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (Chest 2008; 133[suppl]:708S–775S), on page 710S, in column one, Recommendation 2.5.2 (and on page 739S column one), the text should read “For patients with acute ST-segment elevation myocardial infarction receiving fibronolytic therapy who have preserved renal function (< 2.5 mg/dL [220 µmol/L] in males and < 2.0 mg/dL [175 µmol/L] in females), we recommend the use of enoxaparin over UFH, continued up to 8 days (Grade 2A).” The online version has been corrected and that version should be used.

In the June 2008 supplement, in the article by Kearon et al, “Antithrombotic Therapy for Venous Thromboemobolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” (Chest 2008; 133[suppl]:454S–545S), the conflict of interest disclosures from the authors were inadvertently left out. They are as follows: Dr. Kearon discloses that he has received grant monies from the Canadian Institutes for Health Research and the Heart and Stroke Foundation of Canada. He is also on an advisory committee for GlaxoSmithKline and Boehringer Ingelheim. Dr. Agnelli reveals no real or potential conflicts of interest or commitment. Dr. Goldhaber discloses that he has received grant monies from Mitsubishi, Boehringer Ingelheim, Sanofi-Aventis, Eisai, GlaxoSmithKline, and AstraZeneca. He has also received consultant fees from Sanofi-Aventis, Eisai, Bristol-Myers Squibb, and Boehringer Ingelheim. Dr. Raskob discloses that he has served on the speaker bureau and advisory committees and has received consultant fees from Bayer, BMS, Daiichi-Sankyo, Pfizer, Sanofi-Aventis, Takedo and Boehringer Ingelheim. Dr. Comerotta discloses that he is on the speaker bureaus of Sanofi-Aventis, Bristol-Myers Squibb, and GlaxoSmithKline and serves on an advisory committee for ConvaTec, and Bacchus Vascular. He is also a shareholder of LeMaitre Vascular.

In the September 2008 supplement by Tarlo et al, “Diagnosis and Management of Work-Related Asthma: American College of Chest Physicians Consensus Statement” (Chest 2008; 134:1S–41S), some of the subheadings are misleading in the print version. The online version has been corrected and should be used. There is no change to the text, but the level of headings shown on pages 7S–9S, 17S, and 31S–32S is more clear in the corrected online edition. Also, on the Table of Contents pages the Endorsements should read “The Canadian Society of Allergy and Clinical Immunology and The Canadian Thoracic Society”.

In the July 2008 issue, in the correspondence by BaHammam et al, “Positive Airway Pressure Therapy and Daytime Hypercapnia in Patients With Sleep-Disordered Breathing” (Chest 2008;134:218–219), the first author's surname was misspelled. It is BaHammam. It has been corrected in the online edition.


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543